Key facts
- It has raised $11.4M; the latest was Grant ($1.1M) in Nov 2025.
- Notable investors include Innovate UK, UK Research and Innovation, Imperial College London Endowment, Imperial College London, MedTech SuperConnector — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ProtonDx
- ·The full record, as it builds
Funding rounds
No funding rounds for ProtonDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProtonDx
Developer of a portable molecular diagnostic platform designed to deliver rapid, laboratory-grade testing at the point of need. The company offers compact lab-on-a-chip technology that provides PCR-equivalent analysis without a full laboratory, enabling healthcare and veterinary practitioners to gain improved access to fast, accurate diagnostics.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 27
- Website
- protondx.com/
- Ownership
- Privately Held (backing)
ProtonDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProtonDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProtonDx in its N-PORT filings yet. We sweep new filings monthly.